Allogene Therapeutics, Inc. - Common Stock (ALLO)
CUSIP: 019770106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 228,416,724
- Total 13F shares
- 183,617,614
- Share change
- -13,320,916
- Total reported value
- $207,883,293
- Put/Call ratio
- 66%
- Price per share
- $1.13
- Number of holders
- 153
- Value change
- -$15,409,926
- Number of buys
- 68
- Number of sells
- 70
Quarterly Holders Quick Answers
What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 019770106:
Top shareholders of ALLO - Allogene Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| TPG GP A, LLC |
3/4/5
13F
|
10%+ Owner · Company |
8.2%
from 13F
|
18,716,306
|
$59,413,042 | — | 12 Jan 2022 | |
| PFIZER INC |
13F
|
Company |
9.6%
|
22,032,040
|
$32,166,778 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
17,932,906
|
$26,182,043 | — | 31 Mar 2025 | |
| Capital World Investors |
13F
|
Company |
5.4%
|
12,265,330
|
$17,907,382 | — | 31 Mar 2025 | |
| Lynx1 Capital Management LP |
13D/G
13F
|
Company |
5.2%
|
10,874,723
|
$16,747,073 | $0 | 31 Dec 2024 | |
| Darwin Global Management, Ltd. |
13F
|
Company |
4.6%
|
10,449,791
|
$16,197,176 | — | 31 Mar 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
4.9%
|
10,225,851
|
$15,747,811 | -$20,861,062 | 28 Feb 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.5%
|
10,203,329
|
$14,896,860 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.09%
|
215,366
|
$13,332,560 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
8,067,553
|
$11,778,627 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.6%
|
5,853,974
|
$8,546,802 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.2%
|
5,136,797
|
$7,499,723 | — | 31 Mar 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
2.2%
|
4,931,840
|
$7,200,486 | — | 31 Mar 2025 | |
| Eric Thomas Schmidt |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
2,447,772
mixed-class rows
|
$6,396,524 | — | 22 Mar 2023 | |
| Woodline Partners LP |
13F
|
Company |
1.9%
|
4,360,608
|
$6,366,488 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.8%
|
4,206,004
|
$6,141,000 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.7%
|
3,868,750
|
$5,648,375 | — | 31 Mar 2025 | |
| Foresite Capital Management VI LLC |
13F
|
Company |
1.5%
|
3,448,275
|
$5,034,482 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
3,359,438
|
$4,905,807 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.4%
|
3,179,853
|
$4,643,591 | — | 31 Mar 2025 | |
| Wildcat Capital Management, LLC |
13F
|
Company |
1.3%
|
2,920,787
|
$4,264,349 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.2%
|
2,789,777
|
$4,073,074 | — | 31 Mar 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1%
|
2,368,186
|
$3,457,552 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1%
|
2,353,101
|
$3,435,526 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.96%
|
2,200,800
|
$3,213,168 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.94%
|
2,143,110
|
$3,128,940 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.91%
|
2,075,099
|
$3,029,645 | — | 31 Mar 2025 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
0.79%
|
1,798,163
|
$2,625,318 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.68%
|
1,556,700
|
$2,272,782 | — | 31 Mar 2025 | |
| Alison Moore |
3/4/5
|
Chief Technical Officer |
—
mixed-class rows
|
1,105,469
mixed-class rows
|
$2,135,517 | — | 22 Mar 2023 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.6%
|
1,380,118
|
$2,014,972 | — | 31 Mar 2025 | |
| Veer Bhavnagri |
3/4/5
|
General Counsel |
—
class O/S missing
|
556,049
|
$1,765,122 | — | 14 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.52%
|
1,194,410
|
$1,743,839 | — | 31 Mar 2025 | |
| Rafael Amado |
3/4/5
|
EVP of R&D |
—
class O/S missing
|
541,946
|
$1,720,353 | — | 07 Oct 2022 | |
| GILEAD SCIENCES, INC. |
13F
|
Company |
0.51%
|
1,156,689
|
$1,688,766 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.51%
|
1,155,844
|
$1,687,532 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.49%
|
1,116,681
|
$1,630,354 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.42%
|
948,809
|
$1,385,261 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.38%
|
871,597
|
$1,272,532 | — | 31 Mar 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.38%
|
867,250
|
$1,266,185 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.3%
|
688,524
|
$1,005,246 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.29%
|
655,391
|
$956,870 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.24%
|
545,388
|
$796,266 | — | 31 Mar 2025 | |
| ZACKS INVESTMENT MANAGEMENT |
13F
|
Company |
0.23%
|
518,841
|
$757,508 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.21%
|
485,866
|
$709,364 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.21%
|
483,768
|
$706,000 | — | 31 Mar 2025 | |
| Franz B. Humer |
3/4/5
|
Director |
—
mixed-class rows
|
402,907
mixed-class rows
|
$664,215 | — | 18 Jun 2025 | |
| Raiffeisen Bank International AG |
13F
|
Company |
0.18%
|
402,000
|
$622,920 | — | 31 Mar 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.17%
|
380,424
|
$555,420 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.14%
|
331,192
|
$483,540 | — | 31 Mar 2025 |
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2025
As of 30 Jun 2025,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
153 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
183,617,614 shares.
The largest 10 holders included
Pfizer Inc, TPG GP A, LLC, BlackRock, Inc., Capital World Investors, Lynx1 Capital Management LP, Darwin Global Management, Ltd., CITADEL ADVISORS LLC, VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, and GOLDMAN SACHS GROUP INC.
This page lists
154
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
167
Q2 2025 holders
153
Holder diff
-14
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.